Abbott Laboratories (ABT)

NYSE: ABT · Real-Time Price · USD
129.45
-3.23 (-2.43%)
At close: Oct 15, 2025, 4:00 PM EDT
128.80
-0.65 (-0.50%)
After-hours: Oct 15, 2025, 5:49 PM EDT
-2.43%
Market Cap225.30B
Revenue (ttm)43.84B
Net Income (ttm)13.93B
Shares Out 1.74B
EPS (ttm)7.96
PE Ratio16.26
Forward PE23.31
Dividend$2.36 (1.82%)
Ex-Dividend DateOct 15, 2025
Volume14,905,549
Open128.01
Previous Close132.68
Day's Range125.74 - 131.48
52-Week Range110.86 - 141.23
Beta0.70
AnalystsStrong Buy
Price Target146.06 (+12.83%)
Earnings DateOct 15, 2025

About ABT

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]

Sector Healthcare
Founded 1888
Employees 114,000
Stock Exchange NYSE
Ticker Symbol ABT
Full Company Profile

Financial Performance

In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.

Financial Statements

Analyst Summary

According to 18 analysts, the average rating for ABT stock is "Strong Buy." The 12-month stock price target is $146.06, which is an increase of 12.83% from the latest price.

Price Target
$146.06
(12.83% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results

Abbott Laboratories (NYSE:ABT) stock fell around 2.6% on Wednesday after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.

4 hours ago - Benzinga

Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript

Abbott Laboratories (NYSE:ABT) Q3 2025 Earnings Call October 15, 2025 9:00 AM EDT Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, Pre...

4 hours ago - Seeking Alpha

Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway.

The company narrowed its guidance for the second time this year.

9 hours ago - Barrons

Abbott Labs Posts Higher Sales, Reaffirms Outlook

Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults

10 hours ago - WSJ

Abbott posts higher quarterly revenue on strong medical device demand

Abbott reported higher quarterly revenue on Wednesday, driven by strong demand for its medical devices including continuous glucose monitors and heart devices.

10 hours ago - Reuters

Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1 Third-quarter GAAP diluted EPS of $0.94; adjusted dilut...

10 hours ago - PRNewsWire

Stock Market Today: Nasdaq, Dow Jones Futures Rise, Bank Of America, Morgan Stanley, Abbott In Focus—Analyst Warns US 'Going Broke Slowly'

U.S. stock futures advanced on Wednesday following Tuesday's mixed close. Futures of major benchmark indices were higher.

Other symbols: BACMS
12 hours ago - Benzinga

Abbott Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abbott Laboratories (NYSE:ABT) will release earnings results for the third quarter, before the opening bell on Wednesday, Oct. 15.

2 days ago - Benzinga

Abbott Laboratories: There May Be A Surge Coming Next Week (Earnings Preview)

Abbott Laboratories is set to report Q3 earnings, with EPS expectations of $1.30, reflecting 8.3% YoY growth. Abbott's Q2 results showed strong earnings growth, but the stock fell due to expectations ...

6 days ago - Seeking Alpha

Ventric Health Appoints Managed Care Veteran Christopher Abbott to Board of Directors

PASADENA, Calif.--(BUSINESS WIRE)-- #VentricHealth--Ventric Health appoints managed care veteran Chris Abbott to its Board of Directors ahead of commercial expansion of its FDA-approved Vivio System.

9 days ago - Business Wire

Best Dividend Aristocrats For October 2025

Dividend Aristocrats, tracked by NOBL, outperformed SPY in August but lagged year-to-date, with notable dispersion among individual stock returns. Dividend growth remains robust, with 55 of 69 Aristoc...

Other symbols: ADPATOBDXBENCAHCHRWCL
17 days ago - Seeking Alpha

Abbott Hosts Conference Call for Third-Quarter Earnings

ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.

21 days ago - PRNewsWire

These Dividend Stocks Have Big Yields and Are Beating the Odds

Income is lagging growth this year. But companies like Seagate, Newmont, Tapestry and CVS offer the best of both worlds: solid dividend yields and strong stock performance.

Other symbols: ABBVDGROSDYVIG
22 days ago - Barrons

Daily Dividend Report: Kroger, TXN, Philip Morris, Abbott, GE

The Kroger's Board of Directors today declared a quarterly dividend of 35 cents per share to be paid on December 1, 2025, to shareholders of record as of the close of business on November 14, 2025. Th...

Other symbols: GEKRPM
26 days ago - Forbes

1 Dividend King To Hold And 2 Worth Buying Now

It's often said that cash is king, but I would take it one step further. Abbott Laboratories is an AA-rated Dividend King with healthy growth prospects but a rich valuation. I'm waiting for a pullback...

Other symbols: FRTPPG
26 days ago - Seeking Alpha

Abbott Declares 407th Consecutive Quarterly Dividend

ABBOTT PARK, Ill., Sept. 19, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.

26 days ago - PRNewsWire

Inside Abbott's big bet on the future of healthcare

Abbott CEO highlights the company's devices that could make healthcare faster and easier.

5 weeks ago - The Street

Abbott to take $200 million tariff hit: What it means for patients

Abbott's CEO explains what tariffs mean for the company and its patients. Transcript: CAROLINE WOODS: So while you're working on all of that, you're also having to plan for and account for tariffs tha...

6 weeks ago - The Street

Abbott's Navitor™ TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis

Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at lo...

6 weeks ago - PRNewsWire

Abbott CEO reveals the biggest disruptions in healthcare

An inside look into Abbott's momentum across diagnostics and devices, tariff impacts, and how AI will transform healthcare within five years. Transcript: CAROLINE WOODS: Joining me now, Robert Ford, C...

7 weeks ago - The Street

Best Dividend Aristocrats For September 2025

Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A...

7 weeks ago - Seeking Alpha

Best Dividend Kings: August 2025

Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued...

7 weeks ago - Seeking Alpha

Abbott and Big Ten Conference Rally Students, Alumni, and Fans to Save Lives and Win $1 Million for Their School by Donating Blood This College Football Season

All 18 Big Ten universities will go head-to-head in Year 2 of the nationwide challenge, the 'We Give Blood' drive, to inspire the most blood donations from students, alumni, and fans with the winning ...

2 months ago - PRNewsWire

Abbott India's profit climbs on healthy pharmaceutical demand

Drugmaker Abbott India reported an 11.5% rise in first-quarter profit on Tuesday, driven by healthy sales in its mainstay pharmaceuticals segment.

2 months ago - Reuters

Abbott Laboratories Q2 Earnings: Dividends Don't Lie

Abbott's Q2 performance reflects some evenness and the potential headwinds from macroeconomic uncertainties. However, short-term issues like tariffs and drug price control do not fundamentally alter A...

2 months ago - Seeking Alpha